Chimerix, Inc. (NASDAQ:CMRX) Shares Bought by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC raised its stake in Chimerix, Inc. (NASDAQ:CMRX - Free Report) by 78.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 146,186 shares of the biopharmaceutical company's stock after buying an additional 64,420 shares during the quarter. Valeo Financial Advisors LLC owned approximately 0.16% of Chimerix worth $509,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Peapod Lane Capital LLC acquired a new position in shares of Chimerix in the fourth quarter worth $2,626,000. Stoneridge Investment Partners LLC grew its stake in Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company's stock worth $154,000 after purchasing an additional 8,134 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Chimerix by 154.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company's stock worth $2,846,000 after purchasing an additional 496,823 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock valued at $321,000 after purchasing an additional 138,098 shares in the last quarter. 45.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on CMRX shares. Wedbush reiterated an "outperform" rating and issued a $7.00 price objective (up previously from $6.00) on shares of Chimerix in a report on Tuesday. HC Wainwright reiterated a "buy" rating and set a $11.00 price target on shares of Chimerix in a research note on Tuesday.

Insider Activity

In other news, CEO Michael T. Andriole sold 7,370 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares of the company's stock, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is currently owned by company insiders.

Chimerix Stock Up 1.8 %

NASDAQ:CMRX traded up $0.09 during mid-day trading on Thursday, reaching $5.17. 1,726,073 shares of the stock were exchanged, compared to its average volume of 1,656,031. The stock has a market capitalization of $464.99 million, a P/E ratio of -5.50 and a beta of 0.35. Chimerix, Inc. has a 1 year low of $0.75 and a 1 year high of $5.53. The company has a 50 day simple moving average of $3.68 and a 200-day simple moving average of $1.90.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.